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Abstract Autosomal recessive hereditary spastic paraplegia
with thin corpus callosum (HSP-TCC) maps to the SPG11
locus in the majority of cases. Mutations in the KIAA1840
gene, encoding spatacsin, have been shown to underlie
SPG11-linked HSP-TCC. The aim of this study was to
perform candidate gene analysis in HSP-TCC subjects from
Asian families and to characterize disruption of spatacsin
function during zebrafish development. Homozygosity
mapping and direct sequencing were used to assess the
ACCPN, SPG11, and SPG21 loci in four inbred kindreds
originating from the Indian subcontinent. Four novel
homozygous SPG11 mutations (c.442+1G>A, c.2146C>T,
c.3602_3603delAT, and c.4846C>T) were identified, pre-
dicting a loss of spatacsin function in each case. To
investigate the role of spatacsin during development, we
additionally ascertained the complete zebrafish spg11
ortholog by reverse transcriptase PCR and 5′ RACE.
Analysis of transcript expression through whole-mount in
situ hybridization demonstrated ubiquitous distribution, with
highest levels detected in the brain. Morpholino antisense
oligonucleotide injection was used to knock down spatacsin
function in zebrafish embryos. Examination of spg11
morphant embryos revealed a range of developmental
defects and CNS abnormalities, and analysis of axon
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pathway formation demonstrated an overall perturbation of
neuronal differentiation. These data confirm loss of spatacsin
as the cause of SPG11-linked HSP-TCC in Asian kindreds,
expanding the mutation spectrum recognized in this disorder.
This study represents the first investigation in zebrafish
addressing the function of a causative gene in autosomal
recessive HSP and identifies a critical role for spatacsin
during early neural development in vivo.
Keywords Hereditary spastic paraplegia . SPG11 .
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Introduction
Hereditary spastic paraplegia (HSP) encompasses a group of
inherited neurological disorders characterized by degenera-
tion of the corticospinal tract motor neurons and resulting in
progressive lower limb spasticity. Over 35 HSP (or SPG) loci
have been reported [1] and 18 disease genes identified,
accounting for autosomal dominant [2–10], autosomal
recessive [11–17], and X-linked [18, 19] subtypes of HSP.
Importantly, many of the protein products of these genes
share a role in intracellular transport and axonal trafficking
[1, 20], suggesting that a common pathogenic mechanism
may underlie a number of these disorders.
Hereditary spastic paraplegia with thin corpus callosum
(HSP-TCC) is a distinct “complicated” form of autosomal
recessive (AR) HSP associated with thinning of the corpus
callosum. Despite phenotypic overlap with other ARHSPs,
including Mast syndrome (SPG21) [14], agenesis of the
corpus callosum with peripheral neuropathy (ACCPN) [21],
and a form of HSP-TCC with epilepsy [22], the majority of
HSP-TCC cases appear to be linked to the SPG11 locus on
chromosome 15q15.1-q21.1 [23–27]. The SPG11 gene has
been cloned and mutations identified in 11 of 12 European
and North African families analyzed [15]. Since then,
independent confirmation that spatacsin loss-of-function
mutations cause HSP-TCC has been reported in patients of
European, North African, Turkish, Middle Eastern, South
American, and Asian origin. In this paper, we present
further verification of the SPG11 gene as a major genetic
determinant in HSP-TCC by describing novel mutations in
four kindreds of Asian descent.
To gain further insight into the physiological and cellular
bases of HSP-TCC pathology, we have also used
morpholino-based gene knockdown in the zebrafish, Danio
rerio, to investigate spg11 function during development.
Heterozygous mutations in the human SPG4 and SPG8
genes, encoding spastin and strumpellin, respectively, cause
autosomal dominant HSP with predominantly adult onset of
disease [2, 10]. Previous investigations have shown that
knockdown of spg4 and spg8 during zebrafish development
is characterized by aberrant motor neuron axon outgrowth
and widespread CNS developmental defects [10, 28]. Here,
we report initial studies to address the function of a gene
underlying autosomal recessive HSP.
Materials and methods
Patients
We assessed six affected and seven unaffected family
members from four HSP-TCC kindreds of Indian (families
1, 3, and 4) and Pakistani (family 2) descent. Parental
consanguinity was documented in all families. The diagnosis
of HSP-TCC was established according to published criteria
[22]. On examination, all affected individuals demonstrated
significant lower limb spasticity, brisk deep tendon reflexes,
and bilateral extensor plantar responses. Onset of symptoms
occurred between 16 and 20 years of age, with the
exception of the two affected siblings in family 3 presenting
with subnormal intelligence and difficulty in walking since
preschool age. Affected female probands from families 2
and 4 also had mild learning difficulties. Brain MRI
revealed substantial thinning and hypoplasia of the corpus
callosum in all affected cases, together with generalized
moderate cerebral atrophy.
The study was approved by the University Hospitals of
Leicester and Guy’s & St Thomas’ NHS Foundation Trust
local research ethics committees, and all participants
provided written informed consent. Control samples were
of mixed Asian origin, ascertained in relation to a program
of autozygosity mapping with inbred kindreds [29].
Genetic analysis
DNA was extracted from peripheral blood leukocytes by
standard techniques. Microsatellite markers flanking the
ACCPN, SPG11, and SPG21 loci were identified from the
NCBI UniSTS database and amplified by PCR. Genotypes
were assigned from PCR products using an ABI3730xl
automated sequencer and GeneMapper v3.7 software
(Applied Biosystems, Foster City, CA, USA). To confirm
identity-by-descent, additional polymorphic CA-repeat
regions were detected at 43.416 and 43.775 Mb and
genotyped as above (primer details available on request).
Marker positions were assigned according to the NCBI
sequence map (Build 37.1).
All coding exons and intron–exon boundaries of the
SPG21 and SPG11 genes were screened by direct DNA
sequencing. Primers were designed using Primer3 software
[30] or were as previously described [15]. PCR products
were purified with ExoSAP-IT (GE Healthcare, Munich,
Germany), sequenced using BigDye Terminator v3.1
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chemistry (Applied Biosystems), and analyzed on an
ABI3730xl automated sequencer. Sequence traces were
aligned to reference using Sequencher v4.5 software (Gene
Codes Corporation, Ann Arbor, MI, USA).
To directly assess the consequence of the intron 2 splice
site mutation upon transcript translation, total RNA was
extracted from peripheral blood of subjects III:2 and IV:3
with the QIAamp RNA blood mini kit (Qiagen, Crawley,
UK). First-strand complementary DNA (cDNA) synthesis
was performed using the Reverse-iT 1st strand synthesis kit
(ABgene, Epsom, UK). Gene-specific primers SPG11ex1-
intF (5 ′ CAGCCTCCAAGTGCTTTCTT 3 ′) and
SPG11ex4intR (5′ GCTCCTGTTGCTGCTCATTA 3′)
were used for reverse transcriptase PCR (RT-PCR) and
sequencing of messenger RNA (mRNA).
Zebrafish maintenance
Zebrafish embryos were obtained from natural matings,
maintained at 28.5°C, and staged as previously described
[31]. Pigmentation was inhibited by treatment with 0.2 nM
phenylthiourea at 24 h post-fertilization (hpf).
Bioinformatics and cloning of the zebrafish ortholog
Searching the zebrafish genome assembly (Zv7 release v48)
for KIAA1840 orthologs identified an Ensembl gene
(ENSDARG00000045968) on chromosome 25, within contig
Zv7_scaffold2404.1, at position 317,067–343,586 kb. This
gene encodes several overlapping predicted transcripts
sharing homology with the 3′ region of human SPG11 cDNA
(exons 25–40). To delineate the rest of the zebrafish gene,
human cDNA sequence was queried against the zebrafish
genome and EST databases using the TBLASTN algorithm.
A predicted partial mRNA (XM_001346277), located within
Zv7_NA7051.1-2, was identified exhibiting homology with
human SPG11 exons 2–9. Using primer pairs JH37 (5′
TTCTTGTGGGAGGATGTGAG 3′) and JH42 (5′
CTCCGCTCAGCAGGACTCT 3′) and JH43 (5′ GCAGGT
GAGCGTCTGATTTT 3′) and JH44 (5′ AGGAAGCT
GTTGGTCTTGGA 3′), we generated partial cDNA frag-
ments of 1,522 and 1,097 bp. Both PCR products were
cloned into the pCRII-TOPO vector (Invitrogen, Paisley,
UK) to create constructs pCR3′spg11 and pCR5′spg11. The
central 4,575-bp portion (exons 9–33) was TA-cloned into
the pGem-T Easy vector (Promega, Madison, WI, USA),
by long-range RT-PCR with primers zSPG11ex7intF (5′
GTTCTTCATCCGGCTTCAGT 3′) and zSPG11ex34intR
(5′ CGAACAATCCCTTCCAGATT 3′). All clones were
verified using internal sequencing primers. Multiple se-
quence alignments were generated using MultAlin soft-
ware [32], and motif analysis was performed with
QuasiMotiFinder [33].
5′ Ready amplification of cDNA ends
To determine exon 1 of the zebrafish spg11 gene, 5′ ready
amplification of cDNA ends (5′ RACE) was performed
using the GeneRacer RACE ready cDNA kit (Invitrogen)
according to the manufacturer’s guidelines. The gene-
specific reverse primer JH40b (5′ AACACACACGTGTTC
ACCAACAACAC 3′) was used for RT-PCR amplification
with the forward GeneRacer 5′ Primer, and a nested PCR
was performed using zSPG11ex2-3intR (5′ ATGTCGG
CGTGTGTGTGTTTGATGA 3′) and GeneRacer 5′ Nested
Primer. PCR products were gel excised and sequenced
directly with primer zSPG11ex2-3intR. The ATG start site
was identified by translating all three reading frames of the
mRNA sequence using publicly accessible software [34]
and correlating zebrafish and human sequences.
Whole-mount in situ hybridization
and immunohistochemistry
In situ hybridization was performed as previously described
[35]. Antisense and sense digoxigenin-labeled RNA probes
were generated by in vitro transcription from plasmids
pCR5′spg11 and pCR3′spg11. To address the role of spg11
during CNS development, axon pathway formation was
analyzed by anti-acetylated α-tubulin immunohistochemi-
cal labeling at 52 hpf. Alkaline phosphate conjugated
antibodies (6-11B-1) were used for detection (Roche
Applied Science, Mannheim, Germany and Sigma-
Aldrich, St. Louis, MO, USA). Embryos were mounted in
90% glycerol and photographed using a Nikon DS-5Mc
cooled camera system with NIS-Elements Basic Research
(BR) v3.0 software (Nikon Instruments Inc., Amstelveen,
The Netherlands).
Morpholino knockdown of zebrafish spg11
The antisense splice-blocking morpholino oligonucleotides
spg11E2I2 (5′ GTGATGTTCAGTTCTCTTACCGGCG 3′)
and spg11E4I4 (5′ TGTTGGCGGTGTCTGTGCACCTGAA
3′), designed to target the spg11 exon2–intron2 and exon4–
intron4 boundaries, respectively, were synthesized by Gene
Tools, LLC (Philomath, OR, USA). The 5-mismatch mor-
pholino spg11E2I2mm (5′ GTcATcTTgAGTTCTCTTA
gCcGCG 3′) was used as a specificity control. Lyophilized
oligonucleotide resuspended in sterile water was used at a
working concentration of 2 ng/µl containing 0.1% phenol red
and rhodamine for visualization and sorting of injected
embryos. Titrations were performed by injecting 0.5–2 ng
into a single blastomere of 1–2 cell stage embryos, and an
optimal dose minimizing mortality and toxic effects was
determined. Total RNA was isolated from embryos to detect
aberrant splicing events using RT-PCR with primers JH49 (5′
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TCTGAGCAGGAGTGATGCTG 3′) and JH40 (5′ AACA-
CACACGTGTTCACCAAC 3′) across exon 2 and
zSPG11ex3intF (5′ CGTCTG TGAGGCTGTTGTGT 3′)
and zSPG11ex6intR (5′ TCTCGTCTGTCTGCGCTCTA 3′)
across exon 4. PCR products were isolated by gel purification
and sequenced.
Results
Genotyping and mutation detection
Microsatellite genotyping in families 1 and 2 revealed all
affected subjects were heterozygous for ACCPN markers,
but showed homozygosity at the SPG11 (Fig. 1) and SPG21
loci (data not shown). Sequencing of SPG21 excluded this
gene as the cause of HSP-TCC in both families by the
identification of heterozygous SNPs in affected subjects.
Genotyping data for families 3 and 4 were consistent with
exclusion of the ACCPN and SPG21 loci, having hetero-
zygous genotypes in affected cases, and were homozygous
for SPG11 (Fig. 1). Following additional microsatellite
genotyping across the SPG11 locus, the minimal disease
gene interval was defined to a 3.96-Mb region, flanked by
markers D15S779 and D15S659 (Figs. 1 and 2a).
Sequence analysis of the SPG11 gene revealed a splice
donor site mutation in intron 2 (c.442+1G>A), co-
segregating with the disease phenotype in family 1
(Fig. 2b, c). Affected subjects were homozygous and all
unaffected family members were heterozygous for this
mutation, consistent with the genotyping data generated
previously. Using primers in exons 1 and 4, RT-PCR in a
heterozygous parent and an affected subject revealed a wild-
type fragment of 575 bp and a smaller mutant band of 390 bp,
the expected size upon excision of exon 2. Sequencing of the
mRNA transcript confirmed skipping of exon 2 in the mutant
allele, resulting in premature termination and a truncated
protein (p.H86QfsX15; Fig. 2d).
Mutation screening of the SPG11 gene in the remaining
HSP-TCC kindreds identified three further novel mutations
(Fig. 2c). The sequence variants detected in families 2 and
3 also predict generation of truncated transcripts due to
homozygous c.4846C>T and c.2146C>T nonsense mutations
in exons 28 and 11, incorporating stop codons in place of the
native glutamines at positions 1616 and 716, respectively. In
family 4, a homozygous 2-bp deletionwas detected in exon 21
(c.3602_3603delAT), predicting a frameshift leading to
premature termination of the polypeptide chain four amino
acids downstream (p.Y1201LfsX4). None of the identified
mutations were observed in a panel of 180 control chromo-
somes of similar ethnicity.
Fig. 1 Pedigree structures of the four families with genotyping data across the SPG11 locus. Pedigree identifiers indicate subjects from which
DNAwas available. All affected subjects are homozygous for microsatellite markers across this region. Critical recombinations in families 1 and 3
define the disease gene interval between markers D15S779 and D15S659
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Isolation and characterization of the zebrafish spg11 gene
Reference sequence for ∼1.5 kb at each terminus of the
spg11 ortholog was obtained through bioinformatics and 5′
RACE, facilitating amplification of the central portion by
RT-PCR. Complete transcript sequence data have been
deposited with the GenBank data library under accession
numbers FJ217177 (full-length cDNA, 7,140 bp) and
FJ217178 (alternative cDNA, 3,747 bp). Evaluation of
sequence homology between human and zebrafish spatac-
sin revealed 41% identity and 60% similarity across the
length of the proteins (Fig. 3), with particularly high levels
of nucleotide sequence identity across human SPG11 exons
35–36. Using a multiple sequence alignment across
vertebrate species (data not shown), a highly conserved
putative WD repeat signature within this region was
subsequently detected with QuasiMotiFinder (Fig. 3).
Expression of spg11 during zebrafish development
Developmental RT-PCR analysis revealed that spg11 was
expressed both maternally and zygotically, persisting until
at least day 3 of development. Using whole-mount in situ
hybridization, spg11 transcripts were ubiquitously distrib-
uted throughout the embryo at 26 hpf, with increased
expression levels detected in the brain and low levels in the
notochord. Corresponding sense probes produced no
significant hybridization signal (data not shown).
Fig. 2 Novel SPG11 mutations in HSP-TCC families. a Physical map
of chromosome 15q15.1-q21.3, showing the 3.96-Mb minimal
interval harboring the SPG11 (KIAA1840) gene. b Schematic of the
SPG11 gene indicating the locations of the identified mutations. c
Sequence chromatograms. Family 1 carries a c.422+1G>A substitu-
tion at the first nucleotide of intron 2, indicated by the asterisk.
Affected subjects from family 3 carry a c.2146C>T (p.Q716X)
nonsense mutation in exon 11. Amino acid codes are depicted above
the sequence traces. A novel c.3602_3603delAT (p.Y1201LfsX4)
frameshift mutation in exon 21 was detected in family 4. The proband
in family 2 has a c.4846C>T (p.Q1616X) nonsense mutation in exon
28. All unaffected parents are heterozygous for identified mutations. d
RT-PCR analysis in individuals Fam.1-III:2 and -IV:3 shows a wild-
type fragment of 575 bp and mutant fragments of 390 bp. Direct
sequencing of the mutant band confirms skipping of exon 2 with
contiguous sequence from the end of exon 1 into the start of exon 3
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Morpholino knockdown and immunohistochemistry
RT-PCR analysis of spg11E2I2 morphant embryos detected
three transcripts: the wild-type 468-bp fragment, an
abundant 413-bp product, corresponding to an mRNA
lacking the terminal 55 bp of exon 2 and a less abundant
551-bp fragment caused by retention of intron 2. Both mis-
splicing events are predicted to severely truncate the
encoded proteins through introduction of a premature stop
codon in exon 3 (Fig. 4a), providing a good model of the
donor splice site mutation detected in family 1. Morpholino
titration to determine an effective dose for phenotypic
Fig. 3 Multiple sequence alignment of human and zebrafish spatacsin
proteins. Human reference sequence was obtained from the Ensembl
database (ENSP00000261866). Identical amino acid residues are
highlighted in dark gray and residues sharing more than 90%
similarity in light gray. Putative functional domains (i–iv), indicated
by horizontal lines, correspond to the glycosyl hydrolase family 1,
leucine zipper, coiled coil, and Myb domains, described previously
[15]. The highly conserved WD repeat signature predicted by
QuasiMotiFinder is boxed (Prosite ref. PS00678)
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analysis revealed a dose-dependent blocking of splicing
(Fig. 4b). Embryos injected with 0.5 ng demonstrated
phenotypic recovery by 52 hpf, while 2 ng was toxic. The
optimal dose for further analysis of spg11 morphants was
therefore established at 1 ng.
A range of developmental defects was apparent in
spg11E2I2 morphants by 26 hpf. Morphologically, the
embryos had a curly-tail down phenotype (data not shown),
defective brain ventricle formation, and small eyes (Fig. 4c–e).
At 52 hpf, spg11 morphants had developed mild hydroceph-
Fig. 4 Knockdown of zebrafish spg11 function using a splice
blocking morpholino. a Representation of the mRNA transcripts
detected in spg11 control and morphant embryos. Intron–exon
boundaries are depicted in the genomic schematic across exons 1–3.
The asterisk denotes the ATG translational start site. Wild-type mRNA
produces a 468-bp PCR product with primers JH49 and JH40.
Alternatively spliced transcripts from morphant embryos (E2I2a and
E2I2b) lead to premature truncation of translated products by
incorporation of a stop codon (TGA) in exon 3. b Gel image showing
RT-PCR products detected in 26 and 52 hpf zebrafish across a titration
of morpholino doses. Wild-type (468 bp) and alternatively spliced
(413 and 551 bp) PCR products demonstrate that splice blocking is
dose-dependent. c–g Lateral view of the brain. At 26 hpf, morphant
embryos have defective brain ventricle formation (d, arrow) and
smaller eyes. At 52 hpf, spg11 morphant brains have mild hydro-
cephaly and a reduced mid-hindbrain boundary (mhb, arrow) (g). h, i
Lateral view of the trunk at 52 hpf. The typical chevron somite pattern
(dashed lines) is flatter in spg11 morphants. j–s Anti-acetylated α-
tubulin labeling of control (j, l, n, p, r) and spatacsin morphant
embryos (k, m, o, q, s) at 52 hpf. Embryos were injected with 1 ng of
spg11E2I2 morpholino. j, k Ventral view of the brain showing
formation of the optic axons (oa) with reduced retinal ganglion cell
differentiation in spg11 morphants. l, m Lateral view of the brain
highlighting reduced differentiation of facial motor (VII) and bran-
chiomotor (X) neurons in morphant embryos. n–q Dorsal views of the
forebrain, midbrain, and hindbrain. The posterior commissure (pc)
forms but the habenular commissure (hc) fails to project to the dorsal
midline (o, arrow). Morphant hindbrains demonstrate a severe
reduction in neuronal differentiation with an absence of glial curtain
cells and formation of an ectopic cluster of disorganized neurons (q,
arrow). r, s Lateral view of the trunk showing impaired projection and
orientation of the spinal motor neuron axons. ac anterior commissure,
hb hindbrain, tec tectum, tel telencephalon
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aly, the mid-hindbrain boundary was reduced, and the eyes
were still smaller (Fig. 4f, g). In the trunk, the typical
chevron somite pattern appeared flatter in morphant embryos
in comparison to uninjected controls (8% mild, 36%
moderate, 55% severely affected embryos at 1-ng morpho-
lino dose; Fig. 4h, i).
Morphant embryos exhibited a generalized perturbation
of neuronal differentiation, with reduced levels of staining
visible in spg11 morphants compared to controls (Fig. 4j–s).
Although retinal ganglion cell differentiation was reduced
in the eye, the optic axons did form and exit the retina
correctly before projecting to the tectum (Fig. 4j, k).
Analysis of cranial motor neurons revealed that the facial
and branchiomotor neurons of spg11 morphant embryos
were present, but appeared shorter and less differentiated
than those of control embryos (Fig. 4l, m). The posterior
commissure also formed normally by 52 hpf; however, the
habenular commissure failed to project to the dorsal midline
(Fig. 4n, o). In the hindbrain, neuronal differentiation was
severely reduced and glial “curtain” cells were absent. In
addition, an ectopic cluster of disorganized neurons was often
apparent within spg11 morphant hindbrains (Fig. 4p, q). In
the trunk, spinal motor neuron axons projected correctly but
fascicules appeared thinner, suggesting a reduced number of
neurons. Furthermore, there was some evidence of impaired
orientation and axons appeared shortened, implying a failure
to reach their ventral target (Fig. 4r, s). Embryos injected
with an equivalent dose of the spg11E2I2 mismatch
oligonucleotide appeared comparable to uninjected controls,
indicating that the observed phenotype is due to knockdown
of the spg11 transcript (Electronic supplementary materials).
To confirm the specificity of reduction of spg11 activity,
zebrafish embryos were injected with a second spg11-
specific morpholino targeted to the intron 4 splice donor
site, mutation of which has also been previously reported in
the human SPG11 gene [36]. RT-PCR analysis of embryos
injected with the spg11E4I4 morpholino demonstrated
efficient splice blocking, detecting an alternatively spliced
transcript corresponding to retention of intron 4.
Marked CNS abnormalities were also apparent in
spg11E4I4 morphants, and in comparison to spg11E2I2-
injected embryos, a more severe truncation of the spinal
motor neuron axons was observed at higher concentrations
(Electronic supplementary materials). In addition to the CNS
features, embryos also exhibited a range of developmental
defects, including an enlarged heart cavity, which is a relatively
common feature in injected fish, a curly tail and deformities of
the fin, and were generally smaller than the uninjected
controls. As observed with the spg11E2I2 morpholino, the
maximum dose tested was toxic. Statistical analysis of the
distribution of morphological abnormalities by one-way
ANOVA revealed a significant difference between target and
control morpholinos at the 1-ng dose (p<0.0001; Table 1).
Discussion
The genetic basis of the hereditary spastic paraplegias is
rapidly evolving with 18 disease genes now reported,
accounting for approximately 50% of the known loci. In
this study, we report the genetic analysis of four autosomal
recessive HSP-TCC families, each originating from the
Indian subcontinent. Following localization to chromosome
15 by autozygosity mapping, direct sequencing of the
SPG11 gene identified novel pathogenic homozygous
mutations (c.442+1G>A, c.2146C>T, c.3602_3603delAT,
Table 1 Phenotypic characteristics of injected embryos at 52 hpf in comparison to uninjected controls
Target region Dose (ng) No. of embryos (n) Phenotypic characteristics observed
Normal (%) Curly Tail (%) Fin (%) Hydrocephaly (%) Severe deformity (%)
spg11E2I2 0.5 151 57 7 0 7 5
1 158 23 22 19 17 29
1.5 201 18 22 30 15 24
spg11E2I2mm 0.5 80 71 1 0 6 1
1 211 71 4 0 5 6
1.5 395 69 2 2 9 10
spg11E4I4 0.5 87 51 14 5 10 6
1 173 16 36 12 5 19
1.5 227 10 20 23 15 25
Uninjected n/a 81 100 0 0 0 0
Increased morphological features were observed with increasing concentrations of spg11E2I2, spg11E2I2 mismatch (mm) control, and spg11E4I4
morpholinos. The differences between the spg11E2I2 target and mismatch control groups at the 1-ng target dose are statistically significant, as
assessed by one-way ANOVA test (p<0.0001). Embryos with enlarged heart cavities were scored, but this feature was not specific to a loss of
spg11 activity
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and c.4846C>T) in all kindreds. To date, spatacsin
mutations have predominantly been reported in European
(47%), North African (14%), and Chinese (11%) popula-
tions, as detailed in Electronic supplementary materials.
However, only one study has described SPG11 mutations in
patients of subcontinental descent [37], most likely repre-
senting an ascertainment bias but suggesting that SPG11
variation may be a rare cause of HSP in these patients.
All mutations identified in our patients lead to a
truncated protein product, consistent with other reports that
loss of spatacsin function is the pathogenic mechanism
underlying SPG11-linked HSP. While a homozygous G>C
substitution has previously been reported at the intron 2
splice donor site [38], the variant segregating in family 1 is
the first example of a c.442+1G>A mutation and formally
demonstrates that aberrant splicing results in exon 2
skipping. Families 2 and 4 harbor mutations in exons 28
and 21 of the SPG11 gene. Variants have previously been
identified in more than half of all exons; however, <10% of
HSP-TCC cases are accounted for by mutations in exons
18–29, encoding the central region of the spatacsin protein.
Interestingly, previous bioinformatic analysis has indicated
this to be a region of putative structural importance [15].
Although the function of spatacsin remains undetermined,
the putative leucine zipper motif and Myb domain have
implied a possible regulatory function during gene expres-
sion. Through resolution of sequence and amino acid
homology between human and zebrafish, we detected a
highly conserved WD repeat signature across vertebrate
orthologs of spatacsin. Characteristically, WD proteins are
composed of repeating units culminating in tryptophan (W)
and aspartic acid (D) and share a functional role in the
regulation of cellular processes such as cell division, gene
transcription, transmembrane signaling, mRNA modifica-
tion, and vesicle fusion [39]. It remains to be determined
whether the restricted motif detected here reflects a similar
function for spatacsin.
To investigate the role of spatacsin during development,
we have performed whole-mount in situ hybridization
studies in the zebrafish embryo. Previous studies of Spg11
mRNA expression in the rat brain have demonstrated that it
is undetectable in the newborn but is present in the
cerebellum from postnatal days 6–21 [15]. In contrast,
RT-PCR in the zebrafish embryo has detected spg11 mRNA
expression both maternally and zygotically, persisting until
at least 72 hpf. Whole-mount in situ hybridization revealed
that transcripts were ubiquitously distributed throughout the
embryo at 26 hpf with high levels of expression in the
CNS. This ubiquitous expression, similar to that reported
for spg4 [28], is consistent with previous RT-PCR profiling
of the SPG11 gene in human tissues [40] and suggests an
important role for spatacsin during early developmental
processes throughout the embryo.
To specifically assess the functional impact of the c.442+
1G>A splice site mutation, we sought to recapitulate the
phenotype in zebrafish by means of morpholino injection.
We observed a range of developmental defects in spg11
morphant embryos, including CNS abnormalities. Overall,
spg11 morphants exhibited perturbed neuronal differentia-
tion, with markedly reduced levels of immunohistochemical
staining in comparison to control embryos. Consistent with
the features seen in spg4 and spg8 embryos [10, 28], spg11
morphants had a curly-tail phenotype and motor neuron
axons appeared reduced with some evidence of impaired
orientation, albeit less pronounced than in the autosomal
dominant HSP counterparts. While axonal structures within
the brain developed normally, subsequent neuronal projec-
tions appeared to be impeded, particularly within the
forebrain and midbrain regions. The characteristic lower
limb spasticity in HSP is caused by degeneration of the
corticospinal tract motor neurons. The data presented in this
study are in agreement with previous reports demonstrating
a disruption of axon morphogenesis in loss of HSP-specific
gene activity [10, 28], and while the function of the
strumpellin protein remains unknown, this may suggest a
similar role for spatacsin in microtubule dynamics. Further
studies will be required to determine the neuronal-specific
effects of spg11 expression during later development. In
humans, autosomal recessive HSP-TCC typically manifests
during infancy or puberty, and slow disease progression
continues over a period of 10–20 years. In addition to lower
limb spasticity and cognitive impairment, some individuals
exhibit additional features including dysarthria, dysphagia,
and ocular defects. Interestingly, spatacsin knockdown also
appears to impair eye development in spg11 morphants.
In summary, this study provides confirmation that loss of
spatacsin function is the primary molecular defect in the
pathogenesis of SPG11-linked HSP-TCC and points to a
critical role for spatacsin during early neural development. For
clarity, we have also collated all SPG11 mutations reported to
date, providing a comprehensive resource for neurologists and
molecular geneticists in genetic screening for HSP-TCC.
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